Many of the initial examples of the clinical utility of pharmacogenetics were elucidated in the field of oncology. Those examples were largely based on the existence of germline genetic variation that influences the metabolism of cytotoxic drugs. However, with the development of kinase inhibitors, drugs designed to preferentially target altered proteins driving oncogenesis, pharmacogenetics in cancer has shifted to understanding the somatic differences that determine response to these targeted agents. It is becoming increasingly clear that understanding the molecular genetics of cancer will lead to the further development of targeted therapeutics. Therefore, it is imperative that pharmacogenomics researchers understand the motivations and challenges of developing targeted therapies to treat cancer as a paradigm for personalized medicine. However, much of the discussion in the pharmacogenomics community in cancer is still largely focused on the germline variants as predictors of drug toxicity. In light of that fact, this review presents a detailed discussion of the development of commonly used targeted therapies for the treatment of hematological and solid tumors, the somatic mutations that determine response to those therapies, and the mechanisms of drug resistance.
Introduction
Pharmacogenomics is the study of the genetics of interindividual response to drugs and aims at molecular subsetting of patients for more effective therapy. 1 The field of pharmacogenomics is especially important in oncology where most clinically used drugs have a narrow therapeutic window, that is the difference between the dose required to achieve the desired therapeutic effect and that causing toxicity, is small. 2 Therefore, knowledge of genetic variations, inherited or acquired, that may predict differential response to cancer chemotherapy is key to personalized therapy. Genetic variations in drug effect are classified into two groups: those due to either pharmacokinetic or pharmacodynamic factors. The pharmacokinetic factors that influence drug effect involve the drug's absorption, distribution, metabolism and excretion. 3 In contrast, the pharmacodynamic factors that influence drug effect involve the transport of the drug into the cell and the interaction of the drug (ligand) and its target(s). 3 Many of the initial examples from pharmacogenomics in cancer chemotherapy center on understanding the inherited (germline) interindividual differences involved in drug metabolism (Table 1) . 2, [4] [5] [6] [7] However, there are also examples where acquired (somatic) mutations within the tumor DNA are predictive of response to cancer chemotherapy. The elucidation of the signaltransduction networks that drive neoplastic transformation has led to rationally designed cancer therapeutics that target specific molecular abnormalities. 8 These targeted therapeutics, unlike traditional cytotoxic cancer chemotherapeutics, do not have narrow therapeutic indices and therefore have less severe side effects. The less severe side effects experienced by taking targeted therapies is as a result of their greater affinity for inhibiting the activity of somatic alterations of the target kinase(s) that are present within the tumor DNA but absent within the germline. In addition, targeted therapeutics, unlike traditional cytotoxic chemotherapy are available in oral dosage forms for better ease of administration.
Many of the currently known targeted therapeutic agents are protein kinase inhibitors. Kinases are key components of cell signaling pathways involved in neoplastic transformation. Genes that encode protein kinases are often overexpressed or activated as a result of mutations or chromosomal rearrangements in human tumors. Kinase inhibitors are designed as adenosine triphosphate (ATP) mimetics and therefore compete with ATP for binding at the active site. 8 When bound to the active site of the putative kinase(s), kinase inhibitors reduce the activity of the activated protein kinase(s), reducing the cellular oncogenic drive and inducing tumor regression. Interestingly, only a subset of patients respond to these targeted therapies and their response is governed by the presence of specific somatic alterations of the target kinase that are present within the tumor DNA but absent within the germline. In this review, I have highlighted the most common examples whereby somatic mutations within tumor DNA determine clinical response to kinase inhibitors (Table 2) .
BCR-ABL, KIT, PDGFR kinase inhibitors
The first example of the success of small-molecule targeted therapies in treatment of cancer is demonstrated with imatinib, the first small-molecule kinase inhibitor approved for clinical use that targets the breakpoint cluster region (BCR)-ABL protein tyrosine kinase for the treatment of chronic myeloid leukemia (CML). The BCR-ABL protein results from the fusion of the BCR and nonreceptor protein tyrosine kinase ABL resulting from a reciprocal chromosomal translocation t(9;22) producing a shortened chromosome 22, called the Philadelphia (Ph) chromosome. The resultant fusion protein has constitutive tyrosine kinase activity enabling the activation of several signaling pathways such as Ras, PI3K-Akt and Jak-STAT leading to cell proliferation and survival. 9 The BCR-ABL protein is associated predominantly not only with CML but also with acute lymphoblastic leukemia. 9 Imatinib works by binding to and stabilizing an inactive conformation of the BCR-ABL protein kinase. 10, 11 Because imatinib also has specificity for the platelet-derived growth factor receptor, a-polypeptide (PDGFRA) and KIT protein kinases, it is also used in treatment of malignancies associated with dysregulated forms of those proteins.
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Although the initial response to imatinib is dramatic, treatment failure quickly ensues. As is the case with the treatment of CML patients with imatinib, patients initially experience complete cytogenetic and hematological remission. However because imatinib fails to deplete leukemic stem cells that harbor the BCR-ABL fusion protein, 12 some patients develop resistance to imatinib, particularly in the advanced phases of CML and Ph-positive acute lymphoblastic leukemia (ALL). 13 Mechanisms of imatinib resistance include BCR-ABL amplification and overexpression of mRNA and protein. 14, 15 However, the most common mechanism of resistance is the acquisition of somatic point mutations within the kinase domain of the ABL gene. 16 The first point mutation identified as associated with imatinib resistance was T315I. 16 The crystal structure of an analogue of imatinib bound to the ABL kinase domain revealed that the T315 residue was crucial for the interaction between imatinib and ABL. 17 It was also found that a different mutation at the T315 residue (T315V) conferred constitutive kinase activity to ABL and was less sensitive to imatinib compared with wildtype ABL. 18 The T315I point mutation impairs imatinib binding thereby reducing its inhibition of ABL.
There are more than 50 different point mutations in ABL that are associated with imatinib resistance. 13 However, most are rare and six amino-acid residues (Gly250, Tyr253, Glu255, Thr315, Met351 and Phe359) thus far account for 60-70% of imatinib-resistant mutations. 13 Two of the more frequently detected ABL mutants, Y253F and E255K, have been shown to have high in vitro transforming potential. 13 This in vitro finding is consistent with clinical findings that show P-loop mutations such as Y253F and E255K are associated with a greater likelihood of progression to blast crisis and shorter overall survival in imatinib-treated patients. 19 Another ABL mutant, T315I, is generally found in patients with advanced CML, and predicts a worse overall survival compared with other ABL mutations in patients on imatinib therapy. 20 Those drug-resistant BCR-ABL point mutations can be found in imatinib-naïve CML or can be acquired during imatinib treatment. Acquired imatinib resistance involves the reemergence of BCR-ABL tyrosine kinase activity. 21 This suggests that the mutant BCR-ABL protein is still a viable target for inhibition by small-molecule inhibitors. 21, 22 To this end, second generation ABL kinase inhibitors have been designed and have been shown to inhibit the growth of most mutant forms of BCR-ABL resistant to imatinib. One of those drugs, nilotinib, was specifically designed to target imatinib-resistant forms of BCR-ABL, and is approximately 30-fold more potent than imatinib as an ABL inhibitor. 13 Phase I and II trials of nilotinib in patients with imatinibresistant CML in all phases of disease and patients with Phpositive ALL demonstrate significant clinical response to nilotinib. 23 Nilotinib also inhibits KIT and PDGFRB protein kinases and may therefore be used for the treatment of malignancies harboring mutant forms of those proteins. 24 Another second generation ABL kinase inhibitor that demonstrates activity against imatinib resistance is dasatinib. Dasatinib, although not specifically designed to target imatinib-resistant forms of BCR-ABL, is a potent inhibitor of BCR-ABL, Src-family kinases, KIT and PDGFR. 25, 26 In contrast to imatinib and nilotinib, dasatinib binds to the active conformation of the ABL kinase. 27 On the basis of promising data from phase I and II trials of dasatinib, in patients with imatinib-resistant CML and Ph-positive ALL patients, it was recently approved in the United States and Europe for the treatment of adults in all phases of CML with imatinib resistance or intolerance. 28 Dasatinib was also approved for the treatment of patients with Ph-positive ALL with imatinib resistance or intolerance. 29 Because imatinib also has specificity for KIT and PDGFRA proteins, it is used to treat gastrointestinal tumors (GISTs) that harbor mutant forms of those proteins. Most GISTs harbor oncogenic KIT or PDGFRA receptor tyrosine kinase mutations. 30 The KIT or PDGFRA gain-of-function mutations are early events in GIST oncogenesis and lead to the activation of the mitogen-activated protein kinase (MAPK) and signal transducer and activator of transcription (STAT) downstream signaling pathways involved in cell proliferation and survival, respectively. 31 Imatinib, a potent inhibitor of KIT signaling, has recently become first-line treatment of metastatic GIST following in vitro studies suggesting a therapeutic potential for imatinib in a human GIST cell line. 32 Before treatment with imatinib, surgical resection of primary localized GIST was the only chance for cure. 33 GISTs proved refractory to standard chemotherapy and radiation. Recurrence of disease was certain with a predicted 5-year survival of 30%. 34 Prospective trials of imatinib in metastatic GISTs have shown that approximately 80% of patients will respond to imatinib and will achieve stable disease. 35, 36 In addition, 70% of metastatic GIST patients will have at least a 2-year diseasefree survival and 50% will be free of disease progression. 37 As is the case with CML and imatinib response, specific mutations of KIT and PDGFRA in GISTs predict response to imatinib. KIT mutations occur in up to 90% of GISTs and clinical response to imatinib is dependent, at least in part, on the presence of specific KIT mutations. 38 KIT exon 11 mutations are found in 75% of GISTs and result in the abrogation of the juxtamembrane autoinhibition of the KIT kinase. 39 Patients with exon 11 KIT mutations have a higher response rate to imatinib treatment and longer time to treatment failure compared with other KIT or PDGFRA mutations. 40 Patients without detectable KIT or PDGFRA mutation respond less frequently to imatinib treatment compared with exon 11 KIT mutants. 38 However, up to 39% of those patients without KIT or PDGFRA mutations do respond to imatinib. 41 As well, patients with the rare exon 13 KIT mutation or exon 17 PDGFRA mutation may respond to imatinib. 40 These data suggest that imatinib treatment ought to be considered for all GIST patients, regardless of KIT or PDGFRA mutation status. 40 The only exception may be patients with primary imatinib-resistant mutation of PDGFRA (D842V). 40 The majority of metastatic GIST patients will develop resistance to imatinib. The most common resistance mechanisms involve the acquisition of secondary exon 13, 14 or 17 KIT mutations that prohibit imatinib binding. 40 Some of these secondary mutations are intrinsically imatinib-resistant, such as the frequently occurring V654A substitution. 42 However, other mutations such as those involving the N822 residue are intrinsically imatinib sensitive but are associated with clinical imatinib resistance when coincident with an exon 11 KIT mutation. 42 It is therefore crucial to develop more potent inhibitors of KIT and PDGFRA to potentially overcome imatinib resistance. Sunitinib, an inhibitor of KIT, PDGFRA, fms-related tyrosine kinase 3 (FLT3) and vascular endothelial growth factor receptor 2 (VEGFR2), has recently been approved for the treatment of imatinib-resistant GIST and patients unable to tolerate treatment with imatinib. 43 In a randomized phase III trial of sunitinib in patients who had progressed on imatinib therapy, sunitinib was found to prolong median time to tumor progression compared with placebo. 44 However, sunitinib provides only a temporary benefit for imatinib-resistant GIST patients, therefore more therapeutic options are needed. Preclinical studies in GIST cell lines have shown that treatment with heat-shock protein 90 inhibitors resulted in degradation of the KIT oncoprotein and may therefore be of benefit in imatinib-resistant GIST.
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ERBB2 kinase inhibitors
Another example of the success of targeted therapies in the treatment of cancer is that of trastuzumab, a monoclonal antibody against v-erb-b2 erythroblastic leukemia viral oncogene homolog 2 (ERBB2) that was developed to treat breast cancer patients whose tumors overexpress the protein. ERBB2 protein tyrosine kinase amplification and overexpression occurs in approximately 30% of metastatic breast cancers and leads to aberrant signaling through the PI3K and MAPK pathways, resulting in cell proliferation and evasion of apoptosis. 46 Amplified ERBB2 in breast cancer shows clinical correlates with earlier relapse and shorter overall survival. 47 Therefore, a drug, trastuzumab that could target ERBB2 protein in those cancers could increase survival. Trastuzumab was the first genetic-based drug approved for cancer therapy. 48 Unlike the small-molecule kinase inhibitors, which are administered orally, trastuzumab, a monoclonal antibody, is administered intravenously. Trastuzumab is active as a single agent after failure of other chemotherapy regimens. 49 However, primary resistance to trastuzumab monotherapy occurs in approximately 66-88% of ERBB2 overexpressing metastatic breast tumors. 50, 51 Trastuzumab with adjuvant chemotherapy (paclitaxel or docetaxel) significantly improves disease-free and overall survival in patients with early stage ERBB2 overexpressing breast cancers compared with trastuzumab monotherapy. [52] [53] [54] Invariably, the majority of patients who achieve an initial response to trastuzumab-based regimens develop resistance within 1 year. 49 The mechanisms of resistance (primary or acquired) have not been fully elucidated, however there are numerous proposed mechanisms. Elucidating the molecular mechanisms underlying primary or acquired trastuzumab resistance is critical to improving the survival of metastatic breast cancer patients whose tumors overexpress ERBB2. 55 Altered downstream signaling from ERBB2 has been shown to confer primary resistance to trastuzumab. ERBB2 signaling activates the PI3K signaling pathway. Constitutive PI3K/AKT activity has been shown to inhibit trastuzumabmediated cell-cycle arrest and apoptosis. 56 An ERBB2 overexpressing breast cancer cell line, BT474, resistant to trastuzumab had elevated levels of phosphorylated AKT compared to the parent line. 57 The resistant cells were sensitive to a small-molecule inhibitor of PI3K. 57 Patients with phosphatase and tensin homolog (PTEN)-deficient, ERBB2 overexpressing breast tumors have a poorer response to trastuzumab-based therapy. 58 Subsequently, it was shown that in phosphatase and tensin homolog (PTEN)-deficient cells, PI3K inhibitors rescued trastuzumab resistance in vitro and in vivo. 58 Therefore, PTEN loss may serve as a predictor of trastuzumab resistance and PI3K inhibitors may be potential therapies in PTEN-null trastuzumab-resistant tumors. 49 Novel therapeutic strategies are being employed to overcome resistance to trastuzumab. Pertuzumab is a monoclonal ERBB2 antibody that represents a new class of drugs called dimerization inhibitors. 49 Pertuzumab can block signaling by other EGFR family receptors, as well as inhibit signaling in cells expressing normal ERBB2 levels. Pertuzumab sterically blocks dimerization of ERBB2 with EGFR and ERBB3, inhibiting signaling from ERBB2/EGFR and ERBB2/ ERBB3 heterodimers. 59 Pertuzumab is also able to disrupt the interaction between ERBB2 and insulin-like growth factor-I receptor in trastuzumab-resistant cells. 60 Trastuzumab and pertuzumab bind to different epitopes in the extracellular domain of ERBB2. 61, 62 The combination of trastuzumab and pertuzumab produced synergistic apoptosis in ERBB2 overexpressing trastuzumab-naïve breast cancer cells, 63 without any significant effect on the viability of trastuzumab-resistant breast cancer cells. 60 Another alternative therapeutic agent against trastuzumab-resistant tumors is lapatinib, a dual tyrosine kinase inhibitor that targets both EGFR and ERBB2. Binding of lapatinib to EGFR and ERBB2 is reversible but its dissociation is much slower allowing for prolonged downregulation of receptor tyrosine phosphorylation. 49 ERBB2 status and not EGFR status is a determinant of lapatinib activity. 49 It has been shown that the combination of lapatinib with trastuzumab enhanced apoptosis of ERBB2 overexpressing breast cancer cells. 64 Resistance to lapatinib seems to be mediated by increased signaling from the estrogen receptor in estrogen receptor-positive ERBB2 overexpressing breast cancers. 65 This suggests that targeting of both the estrogen receptor and ERBB2 may be beneficial in that subset of cancer patients. 65 A recent phase III trial of trastuzumabresistant ERBB2 overexpressing breast cancer patients demonstrated that the combination of lapatinib and capecitabine resulted in longer median progression-free survival compared with capecitabine alone. 66 ERBB2, a member of the EGFR family, is also overexpressed, to a lesser degree, in lung cancers, specifically adenocarcinomas and large-cell carcinomas and is predictive of poorer outcomes. [67] [68] [69] In addition, intragenic mutations have also been found in the conserved kinase domain of the ERBB2 gene in some lung cancers. 70, 71 The ERBB2 mutations seem to occur exclusively in non-small cell lung cancer (NSCLC) of adenocarcinoma histology and are more common in female patients and never smokers, 71 similar to the clinicophathologic manifestation of EGFR mutations. It was then thought that trastuzumab might be of clinical benefit for the treatment of ERBB2 mutant NSCLC. However, thus far, there has not been demonstrated the benefit of trastuzumab monotherapy or in combination with cancer chemotherapeutics for the treatment of NSCLC with overexpressed ERBB2.
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EGFR kinase inhibitors
To further illustrate the importance of the EGFR family of proteins in cancer progression and treatment, I discuss the timely development of EGFR inhibitors and its subsequent clinical use. EGFR protein tyrosine kinase overexpression has been implicated in numerous cancer types, is associated with poor prognosis, and leads to enhanced signaling through antiapoptotic proteins, Akt and STAT. [76] [77] [78] The fact that EGFR is overexpressed in many cancer types and associated with poor prognosis made it a good candidate for the development of targeted therapeutics. Therefore, two small-molecule inhibitors of EGFR, gefitinib and erlotinib, received speedy approval from the US Food and Drug Administration (FDA) in May 2003 and November 2004, respectively. Gefitinib and erlotinib were approved as singledrug therapy for the treatment of patients with advanced chemotherapy-refractory NSCLC. 79, 80 It was later observed, in the clinic, that only a subset of NSCLC patients achieved dramatic response to these drugs. By molecular genetic analyses, it was found that specific somatic mutations in the conserved kinase domain of the EGFR gene are associated with sensitivity to gefitinib 81, 82 and erlotinib. 83 Recently, however, a large clinical trial comparing gefitinib with placebo in NSCLC patients who had failed other courses of chemotherapy showed no survival benefit from taking gefitinib. 84 Following this report in 2005 the FDA restricted use of gefitinib only to patients who had previously responded to the drug. 85 In contrast, clinical trials have demonstrated that erlotinib improves survival in NSCLC patients whose cancers have progressed on other courses of chemotherapy. 86 Therefore, erlotinib is FDA approved for use in new NSCLC patients with chemotherapy-refractive tumors.
Somatic mutations of EGFR kinase domain are most common in NSCLC and have a distinct clinicophathologic manifestation common in adenocarcinomas, East Asians, women and never smokers. 87 Rare mutations of EGFR are found in head and neck cancers, cholangiosarcomas, colon cancers, ovarian cancers, esophageal cancers and pancreatic cancers. [88] [89] [90] [91] [92] [93] Mutations outside of the kinase domain (extracellular domain) are rare in NSCLC, [81] [82] [83] but are common in gliomas 94 and squamous cell lung cancers. 95 Therefore, the use of EGFR inhibitors in subsets of those tumors may be a viable therapeutic option. In NSCLC, somatic mutations of EGFR are sometimes associated with amplification. 96 Studies have shown that patients with EGFR amplification were more likely to respond to gefitinib or erlotinib and had longer median time to disease progression and overall survival compared to patients with normal EGFR copy number. 97 However, it remains to be established whether amplification of EGFR (wildtype or mutant) contributes to lung cancer development and response to gefitinib or erlotinib. 97 Thus far there are five mutations known to confer sensitivity to EGFR tyrosine kinase inhibitors. The drugsensitive mutations are: point mutations in exon 18 (G719A or G719C), point mutations of exon 21 (L858R and L861Q) and in-frame deletions of exon 19 that eliminates four amino acids (LREA). 98 The most common of these drugsensitive mutations are the exon 19 in-frame deletion and exon 21 missense amino-acid substitution (L858R) accounting for up to 90% of EGFR mutations in NSCLC. 98 In retrospective studies, the association between the presence of EGFR mutation and sensitivity to gefitinib and erlotinib is quite consistent showing 75% response rate for patients with EGFR mutations compared to 10% response rate for patients with wild-type EGFR. [99] [100] [101] [102] [103] Prospective trials have confirmed the association between EGFR mutation and sensitivity to gefitinib and erlotinib. Those studies showed that 78% of patients with somatic exon 19 deletion or exon 21 L858R mutation had radiographic responses to gefitinib and erlotinib. [104] [105] [106] However, there is controversy around what prolongs survival of NSCLC patients; treatment with EGFR inhibitors or presence of EGFR mutation? Large phase III retrospective trials have been conducted where NSCLC patients were randomized to receive either standard cytotoxic chemotherapy alone or standard chemotherapy in combination with gefitinib or erlotinib. 99, 107 Those studies have reported that patients with EGFR mutations have prolonged survival compared with patients with wild-type EGFR treated with gefitinib or erlotinib. Interestingly, the studies have also found that the prolonged survival may occur in the absence of treatment with gefitinib, erlotinib, surgery or standard cancer chemotherapy. 97 In the standard cytotoxic chemotherapy alone treatment arm, patients with EGFR mutation had prolonged progression-free and overall survival compared with patients with wild-type EGFR. 99, 107 Even within the group of NSCLC patients with EGFR mutations, there are reported differences in the clinical course between patients with exon 19 in-frame deletions and patients with exon 21 L858R missense substitution. One study has shown that NSCLC patients with the L858R mutation treated with surgery alone have a prolonged overall survival compared with NSCLC patients with exon 19 deletions. 87 Another study has shown that after treatment with gefitinib or erlotinib, NSCLC patients with EGFR exon 19 deletions have a longer overall survival compared with patients harboring the exon 21 L858R mutation. 98 The molecular basis for such findings is yet unknown.
Therefore, it is no surprise that the mechanism of increased sensitivity of EGFR mutants to gefitinib and erlotinib is still unknown. However, it has been shown that the exon 19 in-frame deletions and exon 21 L858R missense amino-acid substitution confer ligand-independent activation and prolonged kinase activity after ligand stimulation, 81, 82 suggesting that inhibition of the aberrant EGFR signaling may be the predominant mechanism of action of EGFR inhibitors.
As is the case with the aforementioned targeted therapies, imatinib and trastuzumab, despite a dramatic initial response to gefitinib and erlotinib, NSCLC patients with EGFR mutations rarely achieve a complete response and resistance to treatment develops. There are thus far, three EGFR kinase domain mutations associated with drug resistance: an exon 19 point mutation (D761Y), an exon 20 point mutation (T790M) and an exon 20 insertion (D770_N771insNPG). 97 The most common of these drug-resistant mutations is the T790M reported to occur in about 50% of tumors after disease progression and has been predicted to block the binding of gefitinib or erlotinib to the kinase ATP binding pocket. 108, 109 This mutation is analogous to the acquired drug-resistant mutation, T315I, to imatinib seen in GIST and CML. 97 Interestingly, the T790M mutation has been seen in the germline and tumor DNA of family members with hereditary bronchioloalveolar carcinoma. 110 One of the family members with the T790M mutation did not respond to treatment with gefitinib. 110 In vitro data have suggested that irreversible EGFR inhibitors may have activity in patients with acquired resistance to gefitinib or erlotinib. 111, 112 To this end, a phase II trial of HKI-272, an irreversible EGFR kinase inhibitor, is ongoing to determine the efficacy in patients who have progressed after initial treatment with gefitinib or erlotinib. 97 In addition to mutations of EGFR other molecular parameters involved in the EGFR signaling cascade are associated with activity of gefitinib or erlotinib. For example, it has been shown that increased expression of transforming growth factor-a and heregulin, ligands for EGFR and ERBB3, respectively, is associated with poor response to gefitinib. 113, 114 Perhaps competitive inhibitors of those ligands may be a useful therapeutic intervention. It has also been reported that increased copy number of another member of the EGFR family of proteins, ERBB2, in the presence of EGFR mutation in NSCLC, is associated with response to gefitinib. 115 Paradoxically, however, NSCLC patients with intragenic ERBB2 mutations do not respond to gefitinib or erlotinib. 116 That finding suggests there is a distinct genetic context of EGFR mutant NSCLC that predicates response to EGFR inhibitors. Whereas downstream of EGFR signaling, it has been observed that NSCLC patients with KRAS mutations are resistant to gefitinib or erlotinib, 117 and increased phosphorylation of AKT is predictive of response to gefitinib or erlotinib. [118] [119] [120] In light of those observations, one can envisage that the development of molecular diagnostics incorporating any one or combination of those biomarkers may be essential to guide the appropriate use of EGFR inhibitors.
Adding to the complexity of predicting response to EFGR inhibitors, a novel drug-resistant gefitinib mutation has recently been reported that does not involve mutation of EGFR. It was reported that gefitinib-resistant clones from an EGFR-mutant lung cancer cell line displayed amplification of MET oncogene and maintained activation of ERBB3/PI3K/ AKT signaling in the presence of gefitinib. 121 Following the initial observation in cell lines, a panel of 18 gefitinib or erlotinib-resistant primary lung tumors were assessed for MET amplification. MET amplification was found to occur in 22% of those tumors implicating MET amplification in the development of resistance to gefitinib in a subset of lung cancers. 121 Therefore, developing targeted therapies against amplified MET may be beneficial in the treatment of NSCLC patients whose tumors bear the MET amplification and have progressed on EGFR inhibitors.
Discussion
It is clear from the above-mentioned examples, that somatic mutations in cancer can be important in guiding the appropriate use of targeted therapies. As we continue to understand the dysregulated pathways driving oncogenesis this will inevitably lead to the further development of targeted therapies. Elucidation of the myriad genomic abnormalities in cancer will be key to enhancing patient stratification for more accurate diagnosis and treatment. To this end, a few groups are employing systematic highthroughput sequencing screens of cancer genomes in search of other mutated kinases driving oncogenesis. This approach has been fruitful in identifying more frequently mutated oncogenes; BRAF in melanoma, 122 ERBB2 in lung cancer 123 and PIK3CA in colorectal cancer. 124 This has generated interest and investigation into the development and clinical use of small-molecule inhibitors of those kinases (BRAF and PIK3CA) or their signaling partners for the treatment of cancers. [125] [126] [127] [128] Despite the initial success of targeted therapies in producing dramatic responses and tumor regression in genetically defined subgroups of patients, drug resistance inevitably develops. The next challenge facing drug development experts is the design of targeted therapies against those drug-resistant tumors. One way to overcome or abate resistance to single-targeted therapy may be to administer multiple kinase inhibitors or multikinase inhibitors to patients whose tumors may have more than a single mutated kinase. This goal may be achieved the more we learn about the unique somatic mutation patterns of individual tumors and have a plethora of targeted therapies with which to tailor appropriate treatment regimens.
The symbiosis between molecular genetic-based disease classification and genetic-based therapeutic intervention serves as a paradigm for the future of personalized medicine in cancer. Ultimately, however, drug response, even with targeted therapies is not solely dependent on the tumor genetics. The germline genetics also plays a role, especially in drug metabolism. Therefore, as we move forward with implementing genetic-based tests for drug therapy in oncology, it will be important to understand and consider the contribution of both somatic and germline genetics in predicting drug response and toxicity.
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